Personalis Research and Development Expenses 2018-2024 | PSNL
Personalis research and development expenses from 2018 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Personalis Annual Research and Development Expenses (Millions of US $) |
2023 |
$65 |
2022 |
$65 |
2021 |
$49 |
2020 |
$29 |
2019 |
$22 |
2018 |
$14 |
2017 |
$10 |
Personalis Quarterly Research and Development Expenses (Millions of US $) |
2024-09-30 |
$12 |
2024-06-30 |
$13 |
2024-03-31 |
$13 |
2023-12-31 |
$14 |
2023-09-30 |
$17 |
2023-06-30 |
$18 |
2023-03-31 |
$17 |
2022-12-31 |
$17 |
2022-09-30 |
$15 |
2022-06-30 |
$16 |
2022-03-31 |
$17 |
2021-12-31 |
$15 |
2021-09-30 |
$14 |
2021-06-30 |
$12 |
2021-03-31 |
$9 |
2020-12-31 |
$9 |
2020-09-30 |
$7 |
2020-06-30 |
$6 |
2020-03-31 |
$6 |
2019-12-31 |
$7 |
2019-09-30 |
$5 |
2019-06-30 |
$4 |
2019-03-31 |
$5 |
2018-12-31 |
|
2018-09-30 |
$4 |
2018-06-30 |
$4 |
2017-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Generic Drugs |
$0.261B |
$0.073B |
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
|